Arbor Biotechnologies Revenue and Competitors

Claim your profile

Boston, MA USA

Location

#6274

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Arbor Biotechnologies's estimated annual revenue is currently $14.3M per year.(i)
  • Arbor Biotechnologies's estimated revenue per employee is $144,040

Employee Data

  • Arbor Biotechnologies has 99 Employees.(i)
  • Arbor Biotechnologies grew their employee count by 87% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M33-8%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A1150%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M127-27%$135MN/A
#9
$1.7M6-45%$20.9MN/A
#10
$2.8M180%$28.9MN/A

Arbor Biotechnologies is an early stage life sciences company pushing the boundaries of biodiscovery. Arbor’s platform employs a diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – for accelerating the discovery of proteins for improving human health and sustainability.

keywords:N/A

N/A

Total Funding

99

Number of Employees

$14.3M

Revenue (est)

87%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Arbor Biotechnologies News

2022-03-30 - TCR2 Therapeutics, Arbor Biotechnologies Partner on TRuC ...

TCR2 Therapeutics, Arbor Biotechnologies Partner on TRuC-T Cell Therapies. Partnership enables TCR2 to evaluate multiple allogeneic candidates...

2021-11-10 - Arbor Biotechnologies raises $215M to treat genetic diseases

Arbor Biotechnologies has raised a $215 million Series B co-led by Ally Bridge Group, TCG Crossover and Temasek. Based in the Boston area and founded in 2016, the life sciences company is developing precision gene-editing therapeutics to treat liver and CNS disease. Select Additional Investors ...

2021-11-09 - Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics

The most extensive toolbox of proprietary genomic editors in the industry to enable development of curative, next-generation genetic medicines Co-founded by David Walt, Ph.D. and Feng Zhang, Ph.D. CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) — Arbor Biotechnologies, a biotechnology company ...

2021-11-09 - Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics

The most extensive toolbox of proprietary genomic editors in the industry to enable development of curative, next-generation genetic medicines Co-founded by David Walt, Ph.D. and Feng Zhang, Ph.D. CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, a biotechnology compan ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$14.4M99N/AN/A
#2
N/A9943%N/A
#3
$27M100-15%N/A
#4
$32.3M1002%N/A
#5
N/A100-58%N/A